8 rue de la Croix Jarry
244 articles with Cellectis
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the appointment of William (Bill) Monteith to the role of Senior Vice President U.S. Manufacturing.
In its recent third-quarter report, Cambridge, Mass.-based Intellia Therapeutics indicated it is delaying its submission of an Investigational New Drug (IND) application until 2020, from late 2019.
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
Six months after officially launching and one month after securing $120 million in private financing, Allogene Therapeutics is looking to score between $272 and $288 million from an initial public offering.
Biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those adjustments.
Cellectis announced it had appointed Stefan Scherer to the role of senior vice president Clinical Development and deputy chief medical officer.
Cellectis Appoints Stefan Scherer M.D., Ph.D., as Senior Vice President Clinical Development and Deputy Chief Medical Officer
Cellectis announced the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer.
FDA approves UCART123 protocol amendment to accelerate clinical development in AML patients
Allogene Therapeutics announced the implementation of its Scientific Advisory Board (SAB). The SAB is made up of five leaders in oncology, immunology, drug discovery and development, and will consult on strategic and scientific matters.
Cellectis S.A. Annual General Meeting was held on Tuesday, June 26, 2018 in Paris, at its head office.
Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports
Cellectis announced the publication of a study in Scientific Reports, a Nature Publishing Group journal.
Cellectis announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for UCART22.
Cellectis to Present Data at the 2018 ASGCT Annual Meeting
IND filed for UCART22 clinical investigation in ALL patients Allogene takes over Pfizer’s rights under the Research and License Agreement with Cellectis, to accelerate development and commercialization of allogeneic off-the-shelf UCART therapies Harvard’s Wyss Institute partners with Cellectis to recode the human genome using TALEN® gene editing technology
Cellectis announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to initiate a Phase 1 clinical trial for UCART22.
The Wyss Institute for Biologically Inspired Engineering at Harvard University and Cellectis announced that they will collaborate to further advance the Wyss Institute's efforts to recode the entire genome of cell lines derived from humans and other species, and to develop new tools and methods facilitating this goal.
Cellectis has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering to develop CART-T products.
Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies
Allogene intends to assume from Pfizer the global strategic collaboration agreement originally formed with Cellectis in 2014
Cellectis announced its results for the three-month period ended December 31, 2017 and for the year ended December 31, 2017.
Cellectis announced today the issuance of two U.S. patents - US 9,855,297 and US 9,890,393 - for the invention of certain uses of RNA-guided endonucleases, such as Cas9 or Cpf1, for the genetic engineering of T-cells.